Wedbush Downgrades Syros Pharmaceuticals (SYRS) to Neutral
- Wall Street falls as Amazon earnings disappoint
- Amazon (AMZN) Plunges After Missing Sales and Guidance Expectations, Analysts Slash PTs to Reflect Weaker Guidance
- Pinterest (PINS) Tops Profit and Sales Views, But Shares Plunges Over 20% on a Big Monthly User Miss to Prompt Two Downgrades
- Bullard: Fed should taper this fall, go "fairly rapidly" to end early 2022
- Qualtrics International (XM) to Acquire Clarabridge
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
Wedbush analyst David Nierengarten downgraded Syros Pharmaceuticals (NASDAQ: SYRS) from Outperform to Neutral with a price target of $9.00.
Shares of Syros Pharmaceuticals closed at $9.20 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: JPMorgan Downgrades Pinterest Inc (PINS) to Neutral
- Barclays Downgrades Citrix Systems (CTXS) to Underweight
- Syros to Report Second Quarter 2021 Financial Results on Thursday, August 5, 2021
Create E-mail Alert Related CategoriesDowngrades
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!